Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

High Levels of Polypharmacy in Rheumatoid Arthritis—A Challenge Not Covered by Current Management Recommendations: Data From a Large Real-Life Study

2019; SAGE Publishing; Volume: 34; Issue: 3 Linguagem: Inglês

10.1177/0897190019869158

1531-1937

Ana Paula Monteiro Gomides, Cleandro Pires de Albuquerque, Ana Beatriz Vargas‐Santos, Rodrigo Balbino Chaves Amorim, Manoel Barros Bértolo, Paulo Louzada‐Júnior, Isabela Araújo Santos, Rina Dalva Neubarth Giorgi, NATHÁLIA CARVALHO SACILOTTO, Sebastião Cézar Radominski, Fernanda Maria Borghi, Maria Fernanda Brandão de Resende Guimarães, Maria Raquel da Costa Pinto, Gustavo Gomes Resende, Karina Rossi Bonfiglioli, Henrique Carriço, Maria F. L. C. Sauma, Marcel Lobato Sauma, Júlia Brito de Medeiros, Ivânio Alves Pereira, GLAUCIO RICARDO WEBNER DE CASTRO, Claiton Viegas Brenol, Ricardo Machado Xavier, Lícia Maria Henrique da Mota, Geraldo da Rocha Castelar Pinheiro,

Systemic Lupus Erythematosus Research

Background: Rheumatoid arthritis (RA) is associated with high frequency of comorbidities and increased risk of polypharmacy. Although there is a great potential for complications, there is a gap in literature on polypharmacy in patients with rheumatic arthritis. Objective: To evaluate the prevalence and factors associated with polypharmacy in a population in a real-life setting. Methods: A cross-sectional multicenter study was conducted in Brazil. Patients underwent clinical evaluation and medical records analysis. Polypharmacy was considered as a dependent variable. To test independent variables, we used Poisson regression. Results: We evaluated 792 patients (89% female, median age 56.6 years). Median duration of disease was 12.7 years, 78.73% had a positive rheumatoid factor. The median of disease activity score-28 was 3.5 (disease with mild activity), median of the clinical disease activity index score was 9, and median of health assessment questionnaire-disability index was 0.875; 47% used corticosteroids, 9.1% used nonsteroidal anti-inflammatory drugs, 90.9% used synthetic disease-modifying antirheumatic drugs, 35.7% used biologic disease-modifying antirheumatic drugs (DMARDs). In total, 537 (67.9%) patients used 5 or more drugs. Polypharmacy showed a relationship with a number of comorbidities and use of specific drugs (corticosteroids, methotrexate, and biological DMARDs). Conclusion: We found a high prevalence of polypharmacy (67.9%) in RA. Solutions to management this problem should be stimulated.